Showing results (211-220 of 319) with videos related to
Sort By:
Pageof 32
Journal of Neurology|February 8, 2003
Quality of life in patients with orthostatic tremorW Gerschlager, R Katzenschlager, A Schrag, et al.Neurology|July 24, 2002
Anti-basal ganglia antibodies in acute and persistent Sydenham's choreaA J Church, F Cardoso, R C Dale, et al.Journal of Neurology, Neurosurgery, and Psychiatry|September 1, 1989
The effects of oral protein on the absorption of intraduodenal levodopa and motor performanceJ P Frankel, P A Kempster, M Bovingdon, et al.Journal of Neural Transmission|January 1, 1978
Endocrine aspects of bromocriptine therapy in ParkinsonismK M Shaw, A J Lees, S Franks, et al.Journal of Neurochemistry|November 3, 1998
Conjugates of catecholamines with cysteine and GSH in Parkinson's disease: possible mechanisms of formation involving reactive oxygen speciesJ P Spencer, P Jenner, S E Daniel, et al.Journal of Neurology, Neurosurgery, and Psychiatry|June 1, 1989
Levodopa peripheral pharmacokinetics and duration of motor response in Parkinson's diseaseP A Kempster, J P Frankel, M Bovingdon, et al.Neuroscience Letters|October 2, 2001
Strong association of a novel Tau promoter haplotype in progressive supranuclear palsyR de Silva, M Weiler, H R Morris, et al.Brain : a Journal of Neurology|February 7, 2001
Intravenous apomorphine therapy in Parkinson's disease: clinical and pharmacokinetic observationsA J Manson, H Hanagasi, K Turner, et al.Movement Disorders : Official Journal of the Movement Disorder Society|April 1, 1993
Subcutaneous apomorphine in Parkinson's disease: response to chronic administration for up to five yearsA J Hughes, S Bishop, B Kleedorfer, et al.Movement Disorders : Official Journal of the Movement Disorder Society|September 29, 2000
Neuronal intranuclear inclusion disease and juvenile parkinsonismJ D O'Sullivan, H A Hanagasi, S E Daniel, et al.Pageof 32